“…The discovery that PTX had an anti-TNF-α effect stimulated its application into organ ischemia 13,14,19,[21][22][23] . PTX is a nonselective phosphodiesterase inhibitor 12,14,18,19 that decreases TNF-alpha and NFkB gene transcription 13,14,19 , affecting multiple steps in the cytokine/chemokine pathways and exerting beneficial immunomodulatory effects on inflammatory conditions directly and indirectly 12,13,[21][22][23][24][25][26][27] . PTX increased the levels of specific cytokines, increased cyclic adenosine monophosphate (cAMP) levels and decreased TNF-alpha levels, resulting in anti-inflammatory and antioxidant properties 12,18,21,23,25,26 .…”